熱門資訊> 正文
Ligand将以1亿美元收购APEURON Biologics，上调2024年收入前景
2024-07-08 19:17
- Ligand Pharmaceuticals (NASDAQ:LGND) said it will acquire APEIRON Biologics for $100 million in cash.
- Additionally, the company will pay APEIRON shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if QARZIBA royalties exceed certain predetermined thresholds by either 2030 or 2034, respectively.
- The firm is also entering into a stock purchase agreement and is committing to invest up to $4 million in invIOs AG, a privately held spin-off of APEIRON.
- The deal will be immediately accretive to Ligand’s earnings per share by ~$1.00 on an annualized basis, the firm is also increasing its 2024 revenue guidance to be in the range of $140 million to $157 million, and is raising core adjusted EPS guidance to $5.00 to $5.50.
More on Ligand Pharmaceuticals
- Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
- Agenus gains after updating early-stage cancer drug data
- Ligand Pharmaceuticals Non-GAAP EPS of $1.20 beats by $0.37, revenue of $30.98M beats by $3.06M
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
